Liquid Biopsy Market Research Analysis, Characterization and Quantification Forecast by 2030

The Global Liquid Biopsy Market size is estimated to be USD 34.3 million in 2019 and is predicted to reach USD 130.1 million by 2030 with a CAGR of 12.9% from 2020-2030.

Liquid biopsy or fluid biopsy or fluid phase biopsy is the diagnostic testing involves the sampling and analyzing of non-solid biological tissue, such as blood. This technique is majorly used as a diagnostic and monitoring tool for cancer. This technique track tumors and mutations effectively than another process over a duration of time. Many major pharmaceutical and research organization are trying to improve the liquid biopsy procedure.

Access Full Description of this report at:-

https://www.nextmsc.com/report/liquid-biopsy-market

Top Companies: Bio-Rad Laboratories Inc., Biocept, Inc., F. Hoffmann-La Roche AG, Qiagen, Janssen Diagnostics, LLC., Myriad Genetics, Trovagene Inc., Guardant Health Inc., GRAIL, Exosome Sciences, MDX Health SA., Fraunhofer-Gesellschaft, Horizon Discovery, Cynvenio, Diagnologix, Illumina, Inc., CyoTrack and others.

Market Dynamics and Trends:

The major driving factors for the global liquid biopsy market are the rising incidence of cancer, increasing the need for better diagnostic options and increasing government support for research and development. According to the report published by American Cancer Society, by end of 2018, over 1.7 million new cancer cases are expected to be diagnosed in U.S. Increasing spending on research and development activities has supported the growth of the global liquid biopsy market. The Cancer Research UK have spent over 518 million USD on cancer research across the U.K to accelerate progress and increase cancer surviving rate by 75% by 2034. Moreover, reimbursement policies, increasing per capita income of the people, and raising awareness about the availability of diagnostic methods have supported the growth of the market. On the other hand, availability of the alternative diagnostic methods, and long approval time for the drug/devices may slow the growth of the global liquid biopsy market.

Request sample copy of this report at:-

https://www.nextmsc.com/Liquid-Biopsy-Market/request-sample

Market Segmentations and Scope of the Study:

The global liquid biopsy market share is analyzed on the basis of product & services, cancer type, circulating biomarker, and end user. On the basis of product & service, the market is segmented into instruments, reagents, and service. On the basis of cancer type, the market is segmented into lung, colorectal, breast, liver, prostate, and others. On the basis of circulating biomarker, the market is segmented into circulating tumor cells, circulating tumor DNA, extracellular vesicles, and other. On the basis of the end user, the market is categorized into hospitals & laboratories, research centers, and other. The regional analysis of the market comprises of North America, Europe, Asia Pacific, and Rest of the World.

Geographical Analysis:

North America leads the global liquid biopsy markets across owing to the increasing prevalence of various cancers in the region such as breast cancer, lung cancer, and ovarian cancer, among others. Moreover, to meet the upcoming demand and grab the major share of the liquid biopsy market, most of the key players are heavily investing in research and development activities and using modern technologies in R&D in this region which has supported the growth of the market. Increasing government support and growing expenditure on R&D are projected to drive the Europe liquid biopsy market.

Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com

This release was published on openPR.